



US008293284B2

(12) **United States Patent**  
**Baldassarre et al.**

(10) **Patent No.:** **US 8,293,284 B2**  
(45) **Date of Patent:** **\*Oct. 23, 2012**

(54) **METHODS OF REDUCING THE RISK OF OCCURRENCE OF PULMONARY EDEMA IN TERM OR NEAR-TERM NEONATES IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE**

(75) Inventors: **James S. Baldassarre**, Doylestown, PA (US); **Ralf Roskamp**, Chester, NJ (US)

(73) Assignee: **INO Therapeutics LLC**, Hampton, NJ (US)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **12/821,041**

(22) Filed: **Jun. 22, 2010**

(65) **Prior Publication Data**

US 2010/0331405 A1 Dec. 30, 2010

**Related U.S. Application Data**

(63) Continuation of application No. 12/494,598, filed on Jun. 30, 2009, now abandoned.

(51) **Int. Cl.**

**A01N 59/00** (2006.01)

**A61K 33/00** (2006.01)

**C01B 21/24** (2006.01)

**A61M 16/00** (2006.01)

(52) **U.S. Cl.** ..... **424/718**; 128/200.24; 423/405

(58) **Field of Classification Search** ..... None  
See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

5,873,359	A	2/1999	Zapol et al.
6,063,407	A	5/2000	Zapol et al.
6,601,580	B1	8/2003	Bloch et al.
7,557,087	B2	7/2009	Rothbard et al.
2004/0106954	A1	6/2004	Whitehurst et al.
2009/0018136	A1	1/2009	Oppenheimer et al.
2009/0029371	A1	1/2009	Elliott
2009/0149541	A1	6/2009	Stark et al.
2009/0176772	A1	7/2009	Blackburn et al.

**FOREIGN PATENT DOCUMENTS**

EP	1682672	A1	7/2000
WO	WO2005004884	A2	1/2005
WO	WO2006127907	A2	11/2006
WO	WO2010019540	A1	2/2010

**OTHER PUBLICATIONS**

The American Illustrated Medical Dictionary (Dorland, 1914, 7th Ed, p. 113).  
Beghetti et al. (Journal of Pediatrics, 1997, p. 844).  
Macrae et al. (Intensive Care Med 2004, 30, pp. 372-380).

The NIH (Critical Care Therapy and Respiratory Care Section; Nitric Oxide Therapy, May 2000, 13 pages).  
Bolooki (Clinical Application of the Intra-Aortic Balloon Pump 1998, 3rd Ed. pp. 252-253).  
Henrichsen (Journal of Pediatrics 1996, 129(1) p. 183).  
Krohn (The Journal of Thoracic and Cardiovascular Surgery 1999, 117(1) pp. 195-196).  
Semigren (Abstract of J Am Coll Cardiol 1994; 24: 982-988).  
Hayward (Cardiovascular Research 1999; 43:628-638).  
Bocchi (The American Journal of Cardiology 1994, 74, pp: 70-72. 4 pages).  
Beghetti et al. (the Journal of Pediatrics 1997 p. 844).  
Davidson et al. (Pediatrics 1998, 101 (3) pp. 325-334).  
The Neonatal Inhaled Nitric Oxide Study Group (The New England Journal of Medicine 1997, 336(9), pp. 597-604).  
Macrae (Semin Neonatal 1997, 2, 49-58).  
Miller et al. (Archives of Disease in Childhood 1994, 70, F47-F49).  
Weinberger et al. (Toxicology Sciences 2001, 59, 5-16).  
Hurford et al. (Nitric Oxide: Biology and Pathobiology 2000 Academic Press, Chapter 56, pp. 931-945).  
Kazerooni et al. (Cardiopulmonary Imaging 2004, Lippincott Williams & Wilkins, pp. 234-235).  
Wheeler et al. (Pediatric Critical Care Medicine 2007, Springer, p. 278).

Moss et al. (Moss and Adams' Heart Disease in Infants, Children, and Adolescents, 2007, vol. 1, p. 991 in part).

Bocchi et al. The American Journal of Cardiology 1994, 74, pp: 70-72. 4 pages).

"Inhaled Nitric Oxide and Hypoxic Respiratory Failure in Infants With Congenital Diaphragmatic Hernia", The Neonatal Inhaled Nitric Oxide Study Group (NINOS), Pediatrics, vol. 99, No. 6, Jun. 6, 1997, pp. 838-845.

"Inhaled Nitric Oxide in Full-Term and Nearly Full-Term Infants with Hypoxic Respiratory Failure", The Neonatal Inhaled Nitric Oxide Study Group, N Engl J Med, 1997, vol. 336, No. 9, pp. 597-605.

Adatia, et al., "Inhaled Nitric Oxide and Hemodynamic Evaluation of Patients With Pulmonary Hypertension Before Transplantation", Journal of the American College of Cardiology, Elsevier, New York, NY, vol. 25, No. 7, Jun. 1, 1995, p. 1663.

Al-Alaiyan S et al., "Inhaled nitric oxide in persistent pulmonary hypertension of the newborn refractory to high-frequency ventilation", Crit Care, vol. 3, No. 1, 1999, pp. 7-10.

Argenziano, et al., "Inhaled Nitric Oxide is not a Myocardial Depressant in a Porcine Model of Heart Failure", The Journal of Thoracic and Cardiovascular Surgery, 1998, vol. 115, pp. 700-704.

Atz AM et al., "Combined Effects of Nitric Oxide and Oxygen During Acute Pulmonary Vasodilator Testing", Journal of the American College of Cardiology (JACC), vol. 33, No. 3, Mar. 1, 1999, pp. 813-819.

Barrington, et al., Inhaled Nitric Oxide for Preterm Infants: A Systematic Review, Pediatrics 2007; 120; 1088-1099, DOI: 10.1542/peds.2007-0726.

Barst et al., "Nitric Oxide in Combination with Oxygen versus Either Oxygen Alone or Nitric Oxide Alone for Acute Vasodilator Testing in Children with Pulmonary Hypertension: A Multicenter, Randomized Study", INO Therapeutics/Ikaria, Baltimore Convention Center, May 3, 2009, 2 pages, Abstract, downloaded Jul. 2, 2009 from http://127.0.0.1:9080/PAS09A1/view.y?nu=PAS09L1\_1507.

(Continued)

Primary Examiner — Ernst Arnold

(74) Attorney, Agent, or Firm — Fish & Richardson P.C.

(57) **ABSTRACT**

The invention relates methods of reducing the risk or preventing the occurrence of an adverse event (AE) or a serious adverse event (SAE) associated with a medical treatment comprising inhalation of nitric oxide.

## OTHER PUBLICATIONS

- Bland, "Pulmonary vascular dysfunction in preterm lambs with chronic lung disease", *Am J Physiol Lung Cell Mol Physiol* 285: L76-L85, 2003.
- Bocchi EA et al., "Inhaled Nitric Oxide Leading to Pulmonary Edema in Stable Severe Heart Failure", *The American Journal of Cardiology*, vol. 74, Jul. 1, 1994, pp. 70-72.
- Budts W et al., "Residual pulmonary vasoreactivity to inhaled nitric oxide in patients with severe obstructive pulmonary hypertension and Eisenmenger syndrome", *Heart*, vol. 86, 2001, pp. 553-558.
- Clark RH et al., "Low-Dose Nitric Oxide Therapy for Persistent Pulmonary Hypertension: 1-Year Follow-up", *Journal of Perinatology*, (2003) 23:300-303.
- Clark, et al., "Low-Dose Nitric Oxide Therapy for Persistent Pulmonary Hypertension: 1-Year Follow-up", *Journal of Perinatology* 2003; 23: 300-303.
- Cockrill BA et al., "Comparison of the Effects of Nitric Oxide, Nitroprusside, and Nifedipine on Hemodynamics and Right Ventricular Contractility in Patients With Chronic Pulmonary Hypertension", *Chest*, vol. 119, No. 1, Jan. 2001, pp. 128-136.
- Cornfield DN et al., "Randomized, Controlled Trial of Low-dose Inhaled Nitric Oxide in the Treatment of Term and Near-term Infants With Respiratory Failure and Pulmonary Hypertension", *Pediatrics*, vol. 104, No. 5, pp. 1089-1094 (Nov. 5, 1999).
- Cujec, et al., "Inhaled Nitric Oxide Reduction in Systolic Pulmonary Artery Pressure is Less in Patients with Decreased Left Ventricular Ejection Fraction", *Canadian Journal of Cardiology*, 1997, vol. 13 (9), pp. 816-824.
- Davidson D et al., "Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study", *Pediatrics*, Mar. 1998; 101(3 Pt 1):325-34.
- Davidson D et al., "Safety of Withdrawing Inhaled Nitric Oxide Therapy in Persistent Pulmonary Hypertension of the Newborn", *Pediatrics*, vol. 104, No. 2, Aug. 2, 1999, pp. 231-236.
- Day RW et al., "Pulmonary Vasodilatory Effects of 12 and 60 Parts Per Million Inhaled Nitric Oxide in Children with Ventricular Septal Defect", *The American Journal of Cardiology*, vol. 75, Jan. 15, 1995, pp. 196-198.
- Dickstein, et al., "A Theoretic Analysis of the Effect of Pulmonary Vasodilation on Pulmonary Venous Pressure: Implications for Inhaled Nitric Oxide Therapy", *The Journal of Heart and Lung Transplant* Jul. 1996, pp. 715-721.
- Ivy, et al., "Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease", *J Thorac Cardiovasc Surg* 1998; 115:875-882.
- Dorling, "Neurodevelopmental outcome following Nitric Oxide Therapy for Persistent Pulmonary Hypertension in Term Newborn Infants", *Neonatal Intensive Care Unit, Leicester Royal Infirmary*, Aug. 8, 2003, modified Nov. 12, 2003, 3 pages.
- Ferguson, et al., "Inhaled nitric oxide for hypoxemic respiratory failure: Passing bad gas?", *Canadian Medical Association Journal*, Jan. 11, 2000; 162 (1), pp. 85-86.
- Field, Neonatal Ventilation With Inhaled Nitric Oxide Versus Ventilatory Support Without Inhaled Nitric Oxide for Preterm Infants With Severe Respiratory Failure: The INNOVO Multicentre Randomised Controlled Trial (ISRCTN 17821339), "Pediatrics" *Journal* 2005:115:926-936, DOI: 10.1542/peds.2004-1209.
- Findlay, "Paradoxical Haemodynamic Response to Inhaled Nitric Oxide", *International Journal of Intensive Care* 1998 GB, vol. 5, No. 4, 1998, pp. 134-139.
- Finer NN et al., "Randomized, Prospective Study of Low-Dose Versus High-Dose Inhaled Nitric Oxide in the Neonate With Hypoxic Respiratory Failure", *Pediatrics*, vol. 108, No. 4, Oct. 4, 2001.
- Greenough, "Inhaled nitric oxide in the neonatal period", *Expert Opinion on Investigational Drugs*, 2000 Ashley Publications Ltd, 1354-3784, 9 pages.
- Hayward CS et al., "Effect of Inhaled Nitric Oxide on Normal Human Left Ventricular Function", *JACC*, vol. 30, No. 1, Jul. 1997, pp. 49-56.
- Hayward CS et al., "Inhaled Nitric Oxide in Cardiac Failure: Vascular
- Hayward et al., "Left Ventricular Chamber Function During Inhaled Nitric Oxide in Patients with Dilated Cardiomyopathy", *J Cardiovascular Pharmacology*, vol. 34, Iss. 5, Nov. 1999, pp. 749-754, Abstract.
- Henrichsen, et al., "Inhaled Oxide Can Cause Severe Systemic Hypotension", *Journal of Pediatrics*, Mosby-Year Book, St. Louis, MO, vol. 129, No. 1, Jul. 1996, p. 183.
- Inglessis I et al., "Does inhaled nitric oxide support the hemodynamic of spontaneous breathing patients with cardiogenic shock related to right ventricular myocardial infarction? Reply", *JACC*, vol. 45, No. 6, Mar. 15, 2005, pp. 965-966.
- Inglessis I et al., "Hemodynamic effects of inhaled nitric oxide in right ventricular myocardial infarction and cardiogenic shock", *JACC*, vol. 44, No. 4, Aug. 18, 2004, pp. 793-798.
- "Inhaled Nitric Oxide (INO) in Hypoxic Respiratory Failure", Study description, study sponsored by INO Therapeutics, *ClinicalTrials.gov Identifier NCT00922532*, Jun. 16, 2009, 4 pages.
- Krasuski RA et al., "Inhaled Nitric Oxide Selectively Dilates Pulmonary Vasculature in Adult Patients With Pulmonary Hypertension, Irrespective of Etiology", *Journal of the American College of Cardiology (JACC)*, vol. 36, No. 7, Dec. 2000, pp. 2204-2211.
- Lipshultz, "Ventricular dysfunction clinical research in infants, children and adolescents", *Progress in Pediatric Cardiology* 12 (2000) 1-28.
- Loh, et al., "Cardiovascular Effects of Inhaled Nitric Oxide in Patients with Left Ventricular Dysfunction", *Circulation*, Aug. 7, 1994, 90, pp. 2780-2785.
- Magee et al., "Comparison of Supplemental Oxygen and Nitric Oxide for Inhalation plus oxygen in the evaluation of the reactivity of the pulmonary vasculature during Acute Pulmonary Vasodilator Testing", Oct. 1, 2004-Oct. 31, 2006, Reserach project description, 1 page, <http://www.rbht.nhs.uk/research>.
- Matsumoto A et al., "Effect of Inhaled Nitric Oxide on Gas Exchange in Patients with Congestive Heart Failure", *Annals of Internal Medicine*, vol. 130, No. 1, 1999:40-44.
- Morales-Blanhir J et al., "Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension", *Respiratory Medicine*, vol. 98, 2004, pp. 225-234.
- Murray, et al., "Nitric Oxide and Septic Vascular Dysfunction", *Anesth Analg* 2000; 90:89-101.
- Natori S et al., "Inhaled Nitric Oxide Modifies Left Ventricular Diastolic Stress in the Presence of Vasoactive Agents in Heart Failure", *Am J Respir Crit Care Med*, vol. 167, pp. 895-901, 2003.
- Ovodov, et al., "Nitric Oxide: Clinical Applications", *Seminars in Anesthesia, Saunders, CO, New York NY*, vol. 19, No. 2, Jun. 1, 2000, pp. 88-97.
- Pepke-Zaba J et al., "Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension", *The Lancet*, vol. 338, Nov. 9, 1991, pp. 1173-1174.
- Ricciardi MJ et al., Inhaled Nitric Oxide in Primary Pulmonary Hypertension: A Safe and Effective Agent for Predicting Response to Nifedipine, *Journal of the American College of Cardiology (JACC.)* vol. 32, No. 4, Oct. 1998, pp. 1068-1073.
- Roberts, Inhaled Nitric Oxide and Persistent Pulmonary Hypertension of the Newborn, *The New England Journal of Medicine*, Feb. 27, 1997, vol. 336, No. 9, pp. 605-610.
- Rosales, et al., "Hemodynamic Effects Observed with Inhaled Nitric Oxide After Surgical Repair of Total Anomalous Pulmonary Venous Return", *Pediatric Cardiology*, 1999, vol. 20, pp. 224-226.
- Sadiq HF et al., "Inhaled Nitric Oxide in the Treatment of Moderate Persistent Pulmonary Hypertension of the Newborn: A Randomized Controlled, Multicenter Trial", *Journal of Perinatology*, 2003; 23:98-103.
- Sehgal A et al., "Experience with Inhaled Nitric Oxide Therapy in Hypoxic Respiratory Failure of the Newborn", *Indian J Chest Dis Allied Sci*, 2005; 47:245-49.
- Semigran et al., "Hemodynamic Effects of Inhaled Nitric Oxide in Heart Failure", *Journal of American College of Cardiology (JACC)*, vol. 24, No. 4, Oct. 1994, pp. 982-988.

- Smyth RL, "Inhaled nitric oxide treatment for preterm infants with hypoxic respiratory failure", *Thorax*, 2000;55(Suppl 1):S51-S55.
- Steinhorn, RH, "Pulmonary Hypertension, Persistent-Newborn", Updated Apr. 19, 2007, <http://emedicine.medscape.com/article/898437-overview>.
- Steinhorn, et al., "Inhaled nitric oxide enhances oxygenation but not survival in infants with alveolar capillary dysplasia", *The Journal of Pediatrics*, Mar. 1997, pp. 417-422.
- "Use of Inhaled Nitric Oxide", *American Academy of Pediatrics—Committee on Fetus and Newborn*, *Pediatrics* vol. 106, No. 2, Aug. 2000, pp. 344-345.
- Watson, et al., "Clinical and Economic Effects of iNO in Premature Newborns With Respiratory Failure at 1 Year", *Pediatrics* 2009; 124: 1333-1343.
- Steinhorn, "Persistent Pulmonary Hypertension in the Newborn and Infant" 1 (2):287-299 (1987). [downloaded from [www.emedicine.com](http://www.emedicine.com) on Jun. 10, 2008].
- Roberts, et al., *Nitric Oxide and the Lung*, Marcel Dekker, Inc., New York, NY, p. 333-363 (1997).
- Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions, Nitric Oxide, Fifteenth Edition, Elsevier B.V. (2006).
- Ichinose, et al., *Circulation*, 109:3106-3111 (2004).
- INO Therapeutics, NCT00041548 at [ClinicalTrials.gov](http://ClinicalTrials.gov) (2005).
- INO Therapeutics, NCT00551642 at [ClinicalTrials.gov](http://ClinicalTrials.gov) (2007).
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), NCT00005773 at [ClinicalTrials.gov](http://ClinicalTrials.gov) (2005).
- University of Alabama, NCT00732537 at [ClinicalTrials.gov](http://ClinicalTrials.gov) (2008).
- Troncy, et al., *Can J Anaesth*, 44 (9): 973-988 (1997).
- Bloch, et al., *Cardiovasc. Res.* 2007, 75(2): 339-348 (Jul. 15, 2007).
- Azeka, et al., "Effects of Low Doses of Inhaled Nitric Oxide Combined with Oxygen for the Evaluation of Pulmonary Vascular Reactivity in Patients with Pulmonary Hypertension," *Pediatric Cardiol.* Vol. 23, pp. 20-26 (2002).
- Barst et al., "Vasodilator Testing with Nitric Oxide and/or Oxygen in Pediatric Pulmonary Hypertension," *Pediatr. Cardiol.*, vol. 31, pp. 598-606 (2010).
- Beghetti et al., "Inhaled nitric oxide and congenital cardiac disease," *Cardiol. Young*, vol. 11, pp. 142-152 (2001).
- Bichel et al., "Successful weaning from cardiopulmonary bypass after cardiac surgery using inhaled nitric oxide," *Pediatric Anaesthesia*, vol. 7, pp. 335-339 (1997).
- Bin-Nun et al., "Role of iNO in the modulation of pulmonary vascular resistance," *Journal of Perinatology*, vol. 28, pp. S84-S92 (2008).
- Dickstein et al., "A theoretic analysis of the effect of pulmonary vasodilation on pulmonary venous pressure: Implications for inhaled nitric oxide therapy," *J Heart Lung Transplant*, vol. 15, pp. 715-721 (1996).
- Haddad et al., "Use of inhaled nitric oxide perioperatively and in intensive care patients," *Anesthesiology*, vol. 92, pp. 1821-1825 (2000).
- Hayward et al., "Inhaled Nitric Oxide in Cardiac Failure: Vascular Versus Ventricular Effects," *Journal of Cardiovascular Pharmacology*, vol. 27, pp. 80-85 (1996).
- Kieler-Jensen et al., "Inhaled nitric oxide in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance," *J Heart Lung Transplant*, vol. 13, pp. 366-375 (1994).
- Kulik, "Inhaled nitric oxide in the management of congenital heart disease," *Current Opinion in Cardiology*, vol. 11, pp. 75-80 (1996).
- Madriago M.D. et al., "Heart Failure in Infants and Children," *Pediatrics in Review*, Fol. 31, pp. 4-12 (2010).
- Steudel et al., "Inhaled nitric oxide," *Anesthesiology*, vol. 91, pp. 1090-1121 (1999).
- Wessel et al., "Managing low cardiac output syndrome after congenital heart surgery," *Crit. Care Med.*, vol. 29(10) pp. S220-S230 (2001).
- Interview Summary in U.S. Appl. No. 12/821,020, mailed Jan. 25, 2012, 4 pages.
- Fish & Richardson P.C., Statement of the Substance of the Interview and Comments on Examiner's Interview Summary, in U.S. Appl. No. 12/821,020, filed Feb. 27, 2012, 7 pages.
- Fish & Richardson P.C., Statement of Substance of Interview and Comments on Examiner's Interview Summary, in U.S. Appl. No. 12/821,020, filed Apr. 23, 2012, 8 pages.
- INO Therapeutics, "Comparison of Inhaled Nitric Oxide and Oxygen in Patient Reactivity during Acute Pulmonary Vasodilator Testing," downloaded from [clinicaltrials.gov](http://clinicaltrials.gov) on Apr. 23, 2012; first received on Feb. 20, 2008; last updated on Oct. 18, 2010.
- Barst et al., "Vasodilator Testing with Nitric Oxide and/or Oxygen in Pediatric Pulmonary Hypertension," Received: Sep. 14, 2009 / Accepted: Jan. 19, 2010 Springer Science+ Business Media, LLC, 2010, 9 pages.
- Beggs et al., "Cardiac Failure in Children," 17th Expert Committee on the Selection and Use of Essential Medicines, Geneva, Mar. 2009, 31 pages.
- Canadian Office Action mailed May 31, 2011 for Canadian patent application No. 2671029, a counterpart foreign application of U.S. Appl. No. 12/494,598.
- UTMB Respiratory Care Services, "Delivery of Inhaled Nitric Oxide Therapy through an Adult or Pediatric Nasal Cannula," (4 pages) Jul. 2003.
- Douwes et al., "The Maze of Vasodilator Response Criteria," Published online: Nov. 26, 2010, *Pediatr Cardiol.* (2011) 32: pp. 245-246.
- Fraisse et al., "Acute pulmonary hypertension in infants and children: cGMP-related drugs," *Pediatric Crit Care Med* 2010, vol. 11, No. 2 (Suppl.), 4 pages.
- Fraisse et al., "Doppler echocardiographic predictors of outcome in newborns with persistent pulmonary hypertension," *Cardiol. Young*, vol. 14, pp. 277-283, 2004.
- Ichinose et al., "Inhaled Nitric Oxide, A Selective Pulmonary Vasodilator: Current Uses and Therapeutic Potential," *Circulation*, vol. 109, pp. 3106-3111, Feb. 11, 2011.
- INOmax (nitric oxide) for inhalation 100 and 800 ppm (parts per million), drug label insert, 2007, 2 pages.
- Kay et al., "Congestive heart failure in pediatric patients," From the Department of Pediatrics, Duke University Medical Center, 2001, by Mosby, Inc., 6 pages.
- Konduri et al., "A Randomized Trial of Early Versus Standard Inhaled Nitric Oxide Therapy in Term and Near-Term Newborn Infants With Hypoxic Respiratory Failure," *Pediatrics*, vol. 113, pp. 559-564, 2004.
- Malloy, "Nitric Oxide Weaning, RT: For Decision Makers in Respiratory Care," [http://rtmagazine.com/issues/articles/2000-12\\_05.asp](http://rtmagazine.com/issues/articles/2000-12_05.asp), 3 pages, Dec. 2000.
- Rosenberg, "Inhaled nitric oxide in the premature infant with severe hypoxic respiratory failure: A time for caution," *The Journal of Pediatrics*, vol. 133, pp. 720-722, Dec. 1998.
- Advances in Pulmonary Hypertension*, vol. 7(4), pp. 1-418, Winter 2008-2009 (entire issue).
- Non-final Office Action in U.S. Appl. No. 12/820,866, mailed Jun. 8, 2011, 33 pages.
- Lee & Hayes, Amendment in Reply to Office Action in U.S. Appl. No. 12/820,866, mailed Jun. 8, 2011, filed Jul. 8, 2011, 105 pages.
- Final Office Action in U.S. Appl. No. 12/820,866, mailed Aug. 24, 2011, 27 pages.
- Fish & Richardson P.C., Brief on Appeal in U.S. Appl. No. 12/820,866, filed Oct. 4, 2011, 211 pages.
- Examiner Answer in U.S. Appl. No. 12/820,866, mailed Nov. 1, 2011, 27 pages.
- Fish & Richardson P.C., Reply Brief in U.S. Appl. No. 12/820,866, filed Dec. 16, 2011, 21 pages.
- Non-Final Office Action for U.S. Appl. No. 12/820,980, mailed Jun. 10, 2011, 30 pages.
- Lee & Hayes, Amendment in Reply to Office Action in U.S. Appl. No. 12/820,980, mailed Jun. 10, 2011, filed Jul. 11, 2011, 99 pages.
- Final Office Action in U.S. Appl. No. 12/820,980, mailed Sep. 9, 2011, 26 pages.
- Bates, "Inhaled Nitric Oxide: A Selective Pulmonary Vasodilator," 2004, 9 pages.
- Definition of "Contraindication" on [Medicine.net.com](http://www.Medicine.net.com); <http://www.Medicine.net.com>

- Murray et al., "Angiotensin Converting Enzyme Inhibitory Peptides Derived from Food Proteins: Biochemistry, Bioactivity and Production," *Current Pharmaceutical Design*, 2007, vol. 13, pp. 773-791. NIH CC: Critical Care Services, [http://www.cc.nih.gov/ccmd/clinical\\_services.html](http://www.cc.nih.gov/ccmd/clinical_services.html); retrieved Mar. 10, 2011, 3 pages.
- Guidelines for Industry: Clinical Safety Data Management <<[www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidance/ucm073087.pdf](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidance/ucm073087.pdf)>>, Mar. 1995, 17 pages.
- UCI General Clinical Research Center, <<<http://www.gcrc.uci.edu/rsa/aer.cfm>>>, retrieved Sep. 13, 2010, 2 pages.
- Office Action in U.S. Appl. No. 12/821,020, mailed Aug. 13, 2010, 24 pages.
- Lee & Hayes, Replacement Reply Amendment in U.S. Appl. No. 12/821,020, mailed Aug. 13, 2010, filed Feb. 14, 2010, 18 pages.
- Lee & Hayes, Supplemental Reply Amendment in U.S. Appl. No. 12/821,020, filed Apr. 12, 2011, 9 pages.
- Final Office Action in U.S. Appl. No. 12/821,020, mailed Aug. 13, 2010, 32 pages.
- Final Office Action in U.S. Appl. No. 12/821,020, mailed Jun. 27, 2011, 29 pages.
- Fish & Richardson P.C., Supplement to the Reply Brief, U.S. Appl. No. 12/820,866, filed Jan. 3, 2012, 3 pages.
- Fish & Richardson P.C., Amendment in Reply to Final Office Action, U.S. Appl. No. 12/821,020, mailed Jun. 27, 2011, filed Dec. 27, 2011, 153 pages.
- Office Action in U.S. Appl. No. 12/821,020, mailed Jan. 31, 2012, 30 pages.
- Krohn, "Effect of inhaled nitric oxide on left ventricular and pulmonary vascular function," *The Journal of Thoracic and Cardiovascular Surgery*, vol. 117(1), pp. 196-196 (1999).
- Fish & Richardson P.C., Supplemental Amendment in U.S. Appl. No. 12/821,020, filed Apr. 30, 2012, 10 pages.
- Fish & Richardson P.C., Supplemental Remarks in U.S. Appl. No. 12/821,020, filed May 9, 2012, 22 pages.
- European Patent Office minutes of oral proceedings in EP 09 251 949.5, with allowable claims (7 pages), dated May 23, 2012.
- Behera, et al., Nesiritide Improves Hemodynamics in Children with Dilated Cardiomyopathy: A Pilot Study, *Pediatr Cardiol* (2009) 30:26-34.
- Bhagavan, et al., Potential role of ubiquinone (coenzyme Q10) in pediatric cardiomyopathy, *Clinical Nutrition* (2005) 24, 331-338, pp. 331-338.
- Bublik, et al., Pediatric cardiomyopathy as a chronic disease: A perspective on comprehensive care programs, *Progress in Pediatric Cardiology* 25 (2008) 103-111.
- Cox, et al., Factors Associated with Establishing a Causal Diagnosis for Children with Cardiomyopathy, *Pediatrics* vol. 118, No. 4, Oct. 2006, pp. 1519-1531.
- Dermatological Cryosurgery in Primary Care with Dimethyl Ether Propane Spray in Comparison with Liquid Nitrogen, Martinez, et al., *Atencion Primaria*, vol. 18, No. 5, (211, 216), Sep. 30, 1996.
- Dronedarone is Less Effective, But Safer Than Amiodarone in Atrial Fibrillation, Oct. 27, 2009, p. 3, <<<http://www.npci.org.uk/blog/?p=778>>>.
- Ehrenkranz RA, "Inhaled Nitric Oxide in Full-Term and Nearly Full-Term Infants with Hypoxic Respiratory Failure", *The Neonatal Inhaled Nitric Oxide Study Group*, *N Engl J Med*, 1997, vol. 336, No. 9, pp. 597-605.
- Elbl, et al., Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients, *Eur J Pediatr* (2005) 164: 678-684.
- The Encarta Webster's Dictionary of the English Language (2004) is the second edition of the Encarta World Dictionary, published 1999, <<<http://encarta.msn.com/encnet/features/dictionary/dictionaryhome.aspx>>>; used to look up the definitions of "precaution" and "exclusion".
- Green, "Patent Ductus Arteriosus Demonstrating Shunting of Blood", Figure from presentation given Jan. 10, 2011, pp#1.
- Hare, et al., Influence of Inhaled Nitric Oxide on Systemic Flow and
- Harrison's Principles of Internal Medicine, Fauci, et al., p. 1287-1291 and 1360, 12th edition, McGraw Hill, 1998.
- Hayward, et al., Inhaled nitric oxide in cardiology practice, *Cardiovascular Research* 43 (1999) 628-638.
- Huddleston, Indications for heart transplantation in children, *Progress in Pediatric Cardiology* 26 (2009) 3-9.
- James, et al., Treatment of heart failure in children, *Current Paediatrics* (2005) 15, 539-548.
- JP 2009-157623 Office Action dated Feb. 15, 2011, 3 pages.
- Lavigne, et al., Cardiovascular Outcomes of Pediatric Seroreverters Perinatally Exposed to HAART, *Cardiovascular Toxicology* (2004) 04 187-197.
- Lipshultz, The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia, *New England Journal of Medicine* 2004; 351:145-153.
- Lipshultz, et al., Cardiovascular status of infants and children of women infected with HIV-1 (P2C2 HIV): a cohort study, *The Lancet*, vol. 360, Aug. 3, 2002, pp. 368-373.
- Lipshultz, et al., Cardiovascular Trials in Long-Term Survivors of Childhood Cancer, *Journal of Clinical Oncology*, vol. 22, No. 5, Mar. 1, 2004, pp. 769-773.
- Lipshultz, Chronic Progressive Cardiac Dysfunction Years After Doxorubicin Therapy for Childhood Acute Lymphoblastic Leukemia, *Journal of Clinical Oncology*, vol. 23, No. 12, Apr. 20, 2005. 8 pages.
- Lipshultz, Clinical research directions in pediatric cardiology, *Current Opinion in Pediatrics* 2009, 21:585-593.
- Lipshultz, Establishing norms for echocardiographic measurement of cardiovascular structures and function in children, *J Appl Physiol* 99: 386-388, 2005.
- Lipshultz, Frequency of clinically unsuspected myocardial injury at a children's hospital, *American Heart Journal*, vol. 151, No. 4, pp. 916-922.
- Lipshultz, et al., Long-Term Enalapril Therapy for Left Ventricular Dysfunction in Doxorubicin-Treated Survivors of Childhood Cancer, *Journal of Clinical Oncology*, vol. 20, No. 23 (Dec. 1, 2002); pp. 4517-4522.
- Madriago, Heart Failure in Infants and Children, *Pediatrics in Review*, 2010; 31:4-12.
- Michelakis, et al., Oral Sildenafil Is an Effective and Specific Pulmonary Vasodilator in Patients with Pulmonary Arterial Hypertension: Comparison with Inhaled Nitric Oxide, *Circulation* 2002; 105; 2398-2403.
- Miller, et al., Nutrition in Pediatric Cardiomyopathy, *Prog Pediatr Cardiol*, Nov. 2007; 24(1): 59-71.
- Mone, Effects of Environmental Exposures on the Cardiovascular System: Prenatal Period Through Adolescence, *Pediatrics* vol. 113, No. 4, Apr. 2004, pp. 1058-1069.
- NIH Clinical Center, Department Policy and Procedure Manual for the Critical Care Therapy and Respiratory Care Section; Nitric Oxide Therapy, 2000, sections 3.1-3.1.2 & 5.2.3.
- Notification of Reason for Rejection, mailed Jul. 30, 2010, from Japanese Patent Application No. 2009-157623.
- Translated Japanese Office Action mailed Feb. 15, 2011 for Japanese Patent Application No. 2009-157623, a counterpart foreign application for U.S. Appl. No. 12/494,598.
- Pazopanib Plus Lapatinib Compared to Lapatinib Alone in Subjects With Inflammatory Breast Cancer, Apr. 22, 2010, p. 4, *ClinicalTrials.gov*, <<<http://clinicaltrials.gov/ct2/show/NCT00558103>>>.
- Ratnasamy, et al., Associations between neurohormonal and inflammatory activation and heart failure in children, *American Heart Journal*, Mar. 2008, pp. 527-533.
- NIY Clinical Center 2 Critical Care Medicine Department Sample Rotations, Updated Jan. 2007.
- Shapiro, et al., Diagnostic Dilemmas: Diastolic Heart Failure Causing Pulmonary Hypertension and Pulmonary Hypertension Causing Diastolic Dysfunction, *Advances in Pulmonary Hypertension*, Spring 2006; 5(1) 13-20; [http://www.phaonlineuniv.org/sites/default/files/spr\\_2006.pdf](http://www.phaonlineuniv.org/sites/default/files/spr_2006.pdf).
- Sibutramine-metformin Combination vs. Sibutramine and Metformin Monotherapy in Obese Patients, Jul. 15, 2009, p. 3,

- Somarriba, et al., Exercise rehabilitation in pediatric cardiomyopathy, *Progress in Pediatric Cardiology* 25 (2008) 91-102.
- Studel, et al., Inhaled Nitric Oxide—Basic Biology and Clinical Applications, *Anesthesiology*, V 91, No. 4, Oct. 1999, pp. 1090-1121.
- Strauss, et al., Pediatric Cardiomyopathy—A Long Way to Go, *The New England Journal of Medicine*, 348; 17, Apr. 24, 2003, pp. 1703-1705.
- Study of Comparative Effects of Oral Clonidine vs. Oral Diazepam Pre-Medication on the Extent and Duration of Sensory Blockade in Patients Undergoing Vaginal Hysterectomy Under Spinal Anaesthesia, Toshniwal, et al., *Interenet Journal of Anesthesiology*, 2009, <<<http://www.britannica.com/bps/additionalcontent/18/41575551/Study-of-Comparative-Effects-Oral-Clonidine-vs-Oral-Diazepam-Pre-Medication-on-the-Extent-and-Duration-of-Sensory-Blockade-in-Patients-Undergoing-Vaginal-Hysterectomy-Under-Spinal-Anaesthesia>>>.
- van Dalen, Treatment for Asymptomatic Anthracycline-Induced Cardiac Dysfunction in Childhood Cancer Survivors: The Need for Evidence, *Journal of Clinical Oncology*, vol. 21, No. 17, (Sep. 11, 2003), pp. 3375-3379.
- Wilkinson, et al., Epidemiological and outcomes research in children with pediatric cardiomyopathy; discussions from the international workshop on primary and idiopathic cardiomyopathies in children, *Progress in Pediatric Cardiology* 25 (2008) 23-25.
- Au 2009202685 Office Action dated Jun. 17, 2010 (3 pages).
- Au 2009202685 Office Action Response dated Jul. 29, 2010, 19 pages.
- Branson, Inhaled Nitric Oxide in Adults, *The Science Journal of the American Association for Respiratory Care* 1997 Open Forum Abstracts, Dec. 7, 1997, 2 pages, retrieved at <<<http://www.rcjournal.com/abstracts/1997/?id=A00000929>>> on Dec. 22, 2010.
- Braunwald, Heart Failure, chapter 233 of *Harrison's Principles of Internal Medicine*, 14th Edition, 1998, pp. 1287-1291 & 1360.
- Clark, et al., Low-Dose Nitric Oxide Therapy for Persistent Pulmonary Hypertension of the Newborn, *New England Journal of Medicine*, vol. 342, No. 7, pp. 469-474.
- Comparison of Supplemental Oxygen and Nitric Oxide for Inhalation in the Evaluation of the Reactivity of the Pulmonary Vasculature During Acute Pulmonary Vasodilator Testing, [http://clinicaltrials.gov/archive/NCT00626028/2009\\_01\\_12](http://clinicaltrials.gov/archive/NCT00626028/2009_01_12) Jan. 12, 2009.
- Cox, et al., Factors Associated With Establishing a Causal Diagnosis for Children With Cardiology, *Pediatrics*, vol. 118, No. 4, Oct. 4, 2006, pp. 1519-1531, published online Oct. 2, 2006.
- Cuthbertson et al., "UK guidelines for the use of inhaled nitric oxide therapy in adults ICUs\*", *Intensive Care Med* (1997), 23, Springer-Verlag, 1997, pp#1212-pp#1218.
- EP 09251949 Office Action dated Oct. 11, 2010, 5 pages.
- Guideline for Industry; Clinical Safety Data Management: Definitions and Standards for Expedited Reporting, Mar. 1995, 17 pages.
- Headrick, Hemodynamic monitoring of the critically ill neonate, *J Perinat Neonatal Nurs* 1992; 5(4): 58-67.
- INO Therapeutics, LLC, "INOflo for Inhalation 800ppm", package leaflet, 2010, 2.
- JP 2009157623 Office Action dated Feb. 23, 2010, 3 pages.
- JP 2009157623 Office Action dated Jul. 30, 2010, 6 pages.
- JP 2009157623 Office Action response filed Jun. 18, 2010, 37 pages (no translation).
- JP 2009157623 request for accelerated exam filed Jan. 15, 2010 (60 pages).
- JP 2009157623 response filed Nov. 30, 2010, 58 pages.
- Letter of Acceptance for AU 2010202422, dated Oct. 7, 2010.
- Letter of acceptance of AU application 2009202685, dated Aug. 10, 2010, 3 pages.
- Lipschultz, The incidence of pediatric cardiomyopathy in two regions of the United States, *New England Journal of Medicine*, Apr. 24, 2003. <<<http://www.nejm.org/doi/full/10.1056/NEJMoa021715>>>.
- NIH Clinical Center Services, retrieved at <<[http://www.cc.nih.gov/ccmd/clinical\\_services.html](http://www.cc.nih.gov/ccmd/clinical_services.html)>> on Aug. 18, 2010.
- Office Action for AU 2010202422 dated Jul. 9, 2010, 3 pages.
- Office Action from AU 2009202685 dtd Mar. 15, 2010.
- Office Action from AU 2010206032 dated Aug. 16, 2010 (3 pages).
- Office Action Response for AU 2009202685 to Mar. 15, 2010 OA, filed Jun. 8, 2010 (16 pages).
- Office Action Response for JP2007157623 filed on Nov. 12, 2009 (no English translation).
- Office Action Response to AU 2010202422 OA dated Jul. 9, 2010, response filed Sep. 1, 2010.
- PCT/US2010/038652 Search Report dated Jul. 29, 2010, 16 pages.
- Response filed Aug. 18, 2010 to EP Search Report dated May 10, 2010 for EP09251949.
- Search Report from EP 09251949 dated May 10, 2010.
- Towbin, et al., Incidence, Causes, and Outcomes of Dilated Cardiomyopathy in Children, *JAMA*, Oct. 18, 2006—vol. 296, No. 15, pp. 1867-1876.
- Yoshida, Kiyoshi, "Well-illustrated Diagnostics and Treatment of Heart Failure" Professor of Kawasaki Medical University, cardiovascular internal medicine *Circulation Up-to-Date* vol. 2, No. 4, 2007(343), pp. 23-28.
- Weinberger B et al., "The Toxicology of Inhaled Nitric Oxide", *Toxicological Sciences*, 59, pp. 5-16 (2001).
- Weinberger, et al., "Nitric Oxide in the lung: therapeutic and cellular mechanisms of action", *Pharmacology & Therapeutics* 84 (1999) 401-411.
- Wessel DL et al., "Improved Oxygenation in a Randomized Trial of Inhaled Nitric Oxide for Persistent Pulmonary Hypertension of the Newborn", *Pediatrics*, vol. 100, No. 5, Nov. 5, 1997.

\* cited by examiner

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.